Journal for ImmunoTherapy of Cancer (Aug 2021)

CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma

  • Dimo Dietrich,
  • Lutz Trojan,
  • Niklas Klümper,
  • Damian J Ralser,
  • Romina Zarbl,
  • Glen Kristiansen,
  • Marieta Toma,
  • Manuel Ritter,
  • Michael Hölzel,
  • Jörg Ellinger,
  • Markus Eckstein,
  • Danijel Sikic,
  • Katrin Schlack,
  • Andres Jan Schrader,
  • Marc Rehlinghaus,
  • Michèle J Hoffmann,
  • Günter Niegisch,
  • Annemarie Uhlig,
  • Julie Steinestel,
  • Konrad Steinestel,
  • Ralph M Wirtz,
  • Sebastian Strieth

DOI
https://doi.org/10.1136/jitc-2021-002949
Journal volume & issue
Vol. 9, no. 8

Abstract

Read online

No abstracts available.